Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients

Harry Erba • 3 Dec 2016
ASH 2016
Acute Myeloid Leukemia Antibodies Vadastuximab talirine

Press brief by Harry Erba, MD, PhD, of The University of Alabama At Birmingham, Birmingham, AL, on a Phase 1b Study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

More from Harry Erba

6:32
A Phase I trial of DSP-5336, a novel menin inhibitor, in the treatment of AML
Harry Erba • 11 Dec 2023
3:03
SWOG 1318: dasatinib plus blinatumomab in the treatment of older patients with B-ALL
Harry Erba • 11 Dec 2023
5:24
Safety by treatment phase and age when treating FLT3-ITD-mutated AML with quizartinib and chemo
Harry Erba • 11 Dec 2023
3:55
Ziftomenib: a menin inhibitor for R/R NPM1-mutated AML
Harry Erba • 7 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals